Original ResearchPublished 12 October 2026Reporting signals of selected extrapyramidal adverse events with four newer second-generation antipsychotics: a disproportionality analysis of FAERS spontaneous reportsPan Ma · Qin Xiao · Yunpei Zhao · Xin Zhang · Huan Ma · Dan Chen · Linli XieFrontiers in Pharmacologydoi 10.3389/fphar.2026.1921943
Original ResearchPublished 9 October 2026Metformin-associated diarrhea in FAERS: a structured pharmacovigilance study with long-term temporal consistency assessmentShida Chen · Chengan XuFrontiers in Pharmacologydoi 10.3389/fphar.2026.1902348
Original ResearchPublished 28 September 2026Two decades of prescription opioid-related cardiovascular safety signals: a FAERS-based pharmacovigilance study using machine learningLi Ma · Johnna Berryhill · John Ihrie · Ru Chen · Beverly Lyn-Cook · Paul Rogers · Weigong Ge · Ningning Wu · Huixiao Hong · Weida Tong · Wen ZouFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2026.1898403
PerspectivePublished 25 November 2025The role of MedDRA in global pharmacovigilance and public health during COVID-19: pandemic preparedness and responseBrian O’Hare · Heba Ibrahim · Patrick RevelleFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1607642
